Parallax Volatility Advisers
MRSN

Parallax Volatility Advisers’s Mersana Therapeutics MRSN Stock Holding History

Parallax Volatility Advisers’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,148
Closed -$534K – 3438
2020
Q3 		$534K Buy
+1,148
New +$580K ﹤0.01% 2222
2018
Q1 		– Sell
-30
Closed -$12K – 3509
2017
Q4 		$12K Buy
+30
New +$13.1K ﹤0.01% 3770

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Parallax Volatility Advisers's MRSN Position: Q4 2020 in Review

Parallax Volatility Advisers sold out of Mersana Therapeutics (MRSN) in Q4 2020, closing a stake of 1,148 shares — an estimated $534K sold.

Parallax Volatility Advisers first reported a position in MRSN in Q4 2017 and held it in 2 quarters. The position peaked at $534K in Q3 2020. 151 funds tracked by Wall St. Rank hold MRSN as of Q4 2020.

  • Parallax Volatility Advisers reported no remaining Mersana Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Parallax Volatility Advisers sold 1,148 Mersana Therapeutics shares in Q4 2020, an estimated $534K.
  • Parallax Volatility Advisers first reported a position in Mersana Therapeutics in Q4 2017 and held it in 2 quarters.
  • Parallax Volatility Advisers's Mersana Therapeutics position peaked at $534K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2020.

Based on Parallax Volatility Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.